Human epididymis protein 4 as a new diagnostic biomarker for rheumatoid arthritis-associated interstitial lung disease

T. Lin¹, S. Xu¹, Y. Wang², X. Nian³, X. Shan¹, T. Jiang¹, M. Qiu¹

¹Department of Respiratory and Critical Care Medicine, ²Department of Rheumatology and Immunology, ³Department of Gastroenterology, Yantai Yuhuangding Hospital, affiliated with the Medical College of Qingdao, Yantai, Shandong, China.

Abstract

Objective
This study aimed to evaluate the role of human epididymis protein 4 (HE4) in the diagnosis and determination of the severity of interstitial lung disease (ILD) in rheumatoid arthritis (RA) patients.

Methods
HE4 levels in peripheral blood (PB) and bronchoalveolar lavage fluid (BALF) samples were determined via electrochemiluminescence immunoassays in 102 RA patients (46 patients with ILD and 56 patients without ILD) and 51 healthy controls (HCs).

Results
Serum HE4 levels were significantly higher in RA-ILD patients (141.8±65.92 pmol/l) than those in the RA-no ILD patients (82.67±26.17 pmol/l) and healthy controls (35.72±7.6 pmol/l) (p<0.0001). Consistent with serum HE4 levels, BALF HE4 levels were significantly higher in RA-ILD patients (637.6±154.9 pmol/l) than those in the RA-no ILD patients (427.3±111.2 pmol/l) and healthy controls (206.9±30.46 pmol/l) (p<0.0001). In RA-ILD patients, HE4 levels were positively correlated with HRCT (high-resolution computed tomography) fibrosis scores, whereas a significant inverse relationship was found between HE4 levels and lung function parameters (such as, diffusion capacity of the lung for carbon monoxide (DLCO)). The logistic regression analysis showed that high levels of BALF HE4 (≥595 pmol/l) were associated with RA-ILD (odds ratio [OR] =8.09; 95% confidence interval [CI] =1.317–49.682; p=0.024).

Conclusion
Serum and BALF HE4 levels were elevated in RA-ILD patients and strongly associated with the severity of ILD, thus supporting their potential clinical value as a new diagnostic aid for patients with RA-ILD.

Key words
human epididymis protein 4, interstitial lung disease, rheumatoid arthritis

HE4 as a new diagnostic biomarker for RA-ILD / T. Lin et al.

Tiantian Lin, BSc*  
Shufen Xu, BSc*  
Yutie Wang, MD*  
Xueyuan Nian, MD  
Xiaoxi Shan, MD  
Tingshu Jiang, PhD**  
Meihua Qiu, MD**  
*These authors contributed equally to this work and are co-first authors.  
**These authors contributed equally to this work and are co-corresponding authors.  

Please address correspondence to:  
Meihua Qiu  
Department of Respiratory and Critical Care Medicine,  
Yantai Yuhuangding Hospital,  
Affiliated with the Medical College of Qingdao,  
20 Yuhuangding East Road,  
Yantai, Shandong 264200, China.  
E-mail: qiumei901013@163.com  
and to:  
Tingshu Jiang  
E-mail: luxi901013@163.com  

Received on December 7, 2021; accepted in revised form on February 28, 2022.  
© Copyright CLINICAL AND EXPERIMENTAL RHEUMATOLOGY 2022.

Introduction  
Rheumatoid arthritis (RA) is a chronic, systemic, inflammatory disease that involves the synovial joints and it can lead to progressive bone destruction and eventual joint deformity if left untreated (1). RA patients may have extra-articular involvement associated with impairment in physical function, higher morbidity, and premature mortality (2). RA may affect the lung interstitium, airways, and pleurae, whereas pulmonary vascular involvement is less frequent (3). Among those involvements, clinical and preclinical interstitial lung disease (ILD) is the most common and can be detected in 60% of patients with RA (4-7). RA-associated interstitial lung disease (RA-ILD) has a heterogeneous clinical presentation and disease course. ILD is still a major cause of mortality, with a median survival of only 3–9 years after diagnosis (4, 7, 8). Better methods of early diagnosis and monitoring of disease progression in RA-ILD patients are needed to improve the prognosis of patients. At present, the diagnosis of RA-ILD mainly depends on the use of HRCT, but costs and ionising radiation may limit its use in clinical practice. The discovery of new non-invasive biomarkers that could help improve the prospective evaluation of patients with RA-ILD is urgently needed.

Human epididymis protein 4 (HE4) is encoded by the whey acidic protein four-disulfide domain 2 (WFDC2) gene, which is known as a tumour marker in epithelial ovarian cancers (9), lung cancer (10, 11), and endometrial carcinomas (12, 13). Additionally, it has been found to be a potential biomarker for the detection of renal fibrosis and cystic fibrosis, as well as being to a potential target to inhibit fibrosis (14-16). HE4 is elevated in patients with chronic kidney disease, and its concentration is associated with severities in kidney function and renal fibrosis (14). HE4 suppresses the activity of multiple proteases, including serine proteases and matrix metalloproteinases, and it specifically inhibits their capacity to degrade type I collagen, which suggests a functional role of HE4 in the pathogenesis of fibrosis. In lung disease, the elevated expression of HE4 mRNA was also described in cystic fibrosis (CF) lung biopsy specimens compared with non-CF control samples, and HE4 serum levels were positively correlated positively with the overall severity of CF (14). In addition, serum HE4 levels were reportedly higher in patients with IPF than in patients with no respiratory disease (17). In patients with progressive fibrosing interstitial lung disease (PF-ILD), serum HE4 levels were shown to have a positive correlation with the extent of honeycombing on chest high-resolution computed tomography (HRCT) (18). Moreover, higher HE4 levels were associated with an elevated mortality risk, which showed that serum HE4 levels may serve as a potential predictive biomarker for prognosis in PF-ILD. Moreover, a recent study showed that HE4 levels in serum and bronchoalveolar lavage fluid (BALF) were markedly increased in patients with systemic sclerosis-related interstitial lung disease and had a positive correlation with ILD severity (19).

However, little is known about the role of HE4 as a biomarker for the diagnosis of RA-ILD. The purpose of this study was to evaluate the predictive value of HE4 and to examine the correlation between HE4 and ILD severity.

Methods  

Study population  
We recruited 56 consecutive Chinese Han patients with newly diagnosed RA-no-ILD, 46 patients with RA-ILD, and 51 healthy controls (HCs) at the Yantai Yuhuangding Hospital, Qingdao Medical University, China (Table I). The diagnosis of RA was based on the 2010 American College of Rheumatology/European League Against Rheumatism (ACR/ ELAR) criteria (20). Patients were excluded from this study if they presented with signs of other pulmonary diseases (such as pulmonary infection, pulmonary tuberculosis, chronic obstructive pulmonary disease, and ILD caused by pneumocociosis and other causes, a history of malignancy, a history of chronic kidney disease, or a recent clinically significant infection (such as human immunodeficiency virus or viral hepatitis). The diagnosis of ILD was...
based on clinical findings, pulmonary function tests (PFTs), and HRCT scans at entry. The common clinical symptoms of RA-ILD include chronic dry cough, exertional dyspnoea, fatigue, and generalised weakness. Healthy controls included volunteers who were recruited and who were age matched with the case groups without evidence of any diseases. The study protocol (no. 2018-26) was approved by the Ethics Committee of Yantai Yuhuangding Hospital, and all the participants provided written informed consent.

**Pulmonary function tests**
Screening spirometry was performed with the Master Screen PFT System (Jaeger, Germany), in accordance with American Thoracic Society/European Respiratory Society recommendations (21). The forced expiratory volume in 1 second (FEV1), forced vital capacity (FVC), FEV1/FVC ratio, and diffusion capacity of the lung for carbon monoxide (DLCO) were recorded. These values were expressed as a percentage of the predicted value compared with individuals of similar sex, age, weight, and height. A restrictive pattern was defined as a FVC of <80% that predicted in the absence of concomitant obstructive abnormalities.

**Chest high-resolution computed tomography analysis**
All the images were independently evaluated by two experienced thoracic radiologists who were blinded to the clinical data. Discordant interpretations were resolved via a consensus between both radiologists. HRCT results were analysed for ILD scoring. Scoring was performed in each of 3 lung zones: the upper zone (lung apex to aortic arch), the middle zone (aortic arch to inferior pulmonary veins), and the lower zone (inferior pulmonary veins to diaphragm). HRCT scans were semi-quantitatively graded based on lung involvement by using a Likert scale (0=absent, 1=1–25%, 2=26–50%, 3=51–75%, and 4=76–100%) for the extent of 4 categories of parenchymal abnormality (ground glass opacity: hazy parenchymal opacity in the absence of reticular opacity or architectural distortion; lung opacities or architectural distortion; lung mal opacity in the absence of reticular opacities: lucencies or cysts without walls) (22). This scoring system is based on that reported by Kazerooni et al. (23). The scores for each lung zone were averaged for data analysis.

<table>
<thead>
<tr>
<th>Table I. Demographics and clinical data of the study participants.</th>
</tr>
</thead>
<tbody>
<tr>
<td>RA-no-ILD (n=56)</td>
</tr>
<tr>
<td>------------------</td>
</tr>
<tr>
<td>Age (years)</td>
</tr>
<tr>
<td>Female, n (%)</td>
</tr>
<tr>
<td>Smoking history, n (%)</td>
</tr>
<tr>
<td>Current smokers, n (%)</td>
</tr>
<tr>
<td>BMI (kg/m²)</td>
</tr>
<tr>
<td>RA disease duration (years)</td>
</tr>
<tr>
<td>DAS28 (units)</td>
</tr>
<tr>
<td>RF titre (IU/ml)</td>
</tr>
<tr>
<td>RF positive, n (%)</td>
</tr>
<tr>
<td>Anti-CCP antibody titre (IU/ml)</td>
</tr>
<tr>
<td>Anti-CCP antibody positive, n (%)</td>
</tr>
<tr>
<td>Anti-CCP antibody titre positive n (%)</td>
</tr>
<tr>
<td>ANA positive, n (%)</td>
</tr>
<tr>
<td>ESR (mm/h)</td>
</tr>
<tr>
<td>CRP (mg/dl)</td>
</tr>
</tbody>
</table>

RA-ILD: rheumatoid arthritis-associated interstitial lung disease; HCs: healthy controls; BMI: body mass index; DAS: disease activity score; RF: rheumatoid factor; anti-CCP: anti-cyclic citrullinated peptide; ANA: antinuclear antibody; ESR: erythrocyte sedimentation rate; CRP: C-reactive protein.

**Statistical analysis**
All the analyses were performed with SPSS for Windows v. 17.0 (Chicago, Illinois, USA). Continuous variables are summarised as medians (interquartile ranges [IQRs]) or means ± standard deviations (SDs) and categorical data with frequency (percentages). Groups were compared by using an analysis of variance, Student’s t-test, Wilcoxon rank-sum test, or a χ² test (as appropriate). Serum and BALF HE4 levels of the different groups were compared by using an analysis of variance. Correlations were assessed by using a Pearson correlation test or a Spearman’s rank test. The receiver-operating characteristic (ROC) curve was used to analyse the value of HE4 in the diagnosis of RA-ILD. Sensitivity, specificity, and positive and negative predictive values were calculated based on cut-off levels that were identified in the ROC analyses that maximised sensitivity and specificity. A multivariate logistic regression model was built to identify risk factors for ILD in RA patients. A p-value <0.05 was considered to be statistically significant.

**Results**

**Demographic characteristics**
The characteristics of 56 patients with RA-no-ILD, 46 patients with RA-ILD, fibrosis: reticular opacification, traction bronchiectasis, and bronchiolectasis; honeycombing: clustered air-filled cysts with dense walls; and emphysema: lucencies or cysts without walls) (22). This scoring system is based on that reported by Kazerooni et al. (23). The scores for each lung zone were averaged for data analysis.

**Sample collection and measurements of HE4**
Serum samples were obtained from each subject. BALF specimens were obtained from 38 RA-ILD patients and 30 RA-no-ILD patients according to a standardised protocol (24). Twenty-one subjects underwent routine healthy examinations, received diagnostic bronchoscopies and showed normal BAL cytology measurements. The BAL cell differentials of each group are shown in Table II. The obtained serum and BALF samples were centrifuged immediately at room temperature. All the serum samples and BALF supernatant samples were stored at -80°C prior to use. The concentration of HE4 was determined via an electrochemiluminescence immunoassay (ECLI, Roche Diagnostics GmbH, Mannheim, Germany) in the laboratory at Yantai Yuhuangding Hospital according to the manufacturer’s instructions.

Clinical and Experimental Rheumatology 2022

**Clinical and Experimental Rheumatology 2022**

HE4 as a new diagnostic biomarker for RA-ILD / T. Lin et al.

2169
and 51 healthy controls are summarised in Table I. Twenty-seven RA-ILD patients (58.7%) showed respiratory symptoms, of which shortness of breath was most frequent (18/27, 66.7%).

The mean age of the RA-ILD patients was 63.35±8.16 years and that of RA-non-ILD cases was 58.29±8.83 years. RA-ILD patients were older than RA no-ILD patients and healthy controls (p<0.05). RA-ILD patients had higher rheumatoid factor (RF) and anti-cyclic citrullinated peptide (ACCP) antibody titres and higher C-reactive protein (CRP) levels than RA no-ILD patients (p<0.05), whereas other general biological indices, such as body mass index (BMI), the duration of the disease process, disease activity score (DAS28), antinuclear antibody (ANA) positivity, and erythrocyte sedimentation rate (ESR), showed no significant differences between the two groups. Laboratory findings are shown in Table II.

### Increased serum and BALF HE4 levels in RA-ILD patients

We first investigated the HE4 levels in serum and BALF among the different groups. As shown in Fig. 1a, the serum HE4 levels were significantly elevated in RA-ILD patients (141.8±65.92 pmol/l) compared with RA-no-ILD patients (82.67±26.17 pmol/l) and healthy control subjects (35.72±7.6 pmol/l) (p<0.0001). In addition, the serum HE4 levels were also higher in RA-no-ILD patients (82.67±26.17 pmol/l) than in healthy controls (35.72±7.6 pmol/l) (p<0.0001). As shown in Fig. 1b, BALF HE4 levels were also significantly elevated in RA-ILD patients (637.6±154.9 pmol/l) compared with RA-no-ILD patients (427.3±111.2 pmol/l) and healthy control subjects (206.9±30.46 pmol/l) (p<0.0001). In addition, the BALF HE4 levels were also higher in RA-no-ILD patients (427.3±111.2 pmol/l) than in healthy controls (206.9±30.46 pmol/l) (p<0.0001). Moreover, a significant relationship was observed between the serum and BALF HE4 levels (r=0.7606, p<0.0001, Fig. 2).

### Increased HE4 levels correlated with ILD severity in RA-ILD patients

We also explored the correlation between HE4 levels and ILD severity in RA patients by using a Spearman analysis. We found that HE4 levels in serum and BALF were apparently correlated with HRCT fibrosis scores in the RA-ILD group (Fig. 3a: r=0.5256, p=0.0004; Fig. 3b: r=0.4063, p=0.0114). In addition, we evaluated the relationship between HE4 levels and PFTs. In the RA-ILD group, the HE4 levels in serum and BALF showed a significant inverse correlation with DLCO% pred (Fig. 4a: r=-0.3848, p=0.0393; Fig. 4b: r=-0.4472, p=0.02). Furthermore, the relationship between HE4 levels and the values of FVC% pred was analysed in RA-ILD patients; although the p-value was not significant, an inverse tendency was found (Fig. 4c: r=-0.1655, p=0.3909; Fig. 4d: r=-0.3015, p=0.1344).

### Table II. Laboratory findings in patients and healthy controls.

<table>
<thead>
<tr>
<th></th>
<th>RA-ILD (n=38)</th>
<th>RA-no-ILD (n=30)</th>
<th>HCs (n=21)</th>
<th>p-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>PaO2 (mmHg)</td>
<td>73.40±10.31</td>
<td>95.14±3.15</td>
<td>97.65±1.51</td>
<td>0.000</td>
</tr>
<tr>
<td>Pulmonary function test</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>FEV1%, predicted</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>VC%, predicted</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>DLCO%, predicted</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ILD score</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>GOO score</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Fibrosis score</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Honeycombing score</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Emphysema score</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>BAL cellular profile</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Macrophage, %</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Lymphocyte, %</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Neutrophil, %</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Eosinophil, %</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Serum HE4 (pmol/l)</td>
<td>141.8±65.92</td>
<td>82.67±26.17</td>
<td>35.72±7.6</td>
<td>0.000</td>
</tr>
<tr>
<td>BALF HE4 (pmol/l)</td>
<td>637.6±154.9</td>
<td>427.3±111.2</td>
<td>206.9±30.46</td>
<td>0.000</td>
</tr>
</tbody>
</table>


**Fig. 1.** Serum (a) and BALF (b) HE4 levels in patients with RA-ILD or RA-no-ILD and HCs. BALF: bronchoalveolar lavage fluid; HE4: human epididymis protein 4; RA-ILD: rheumatoid arthritis-associated interstitial lung disease; HCs healthy controls.

**Fig. 2.** Associations between HE4 in serum and BALF. BALF: bronchoalveolar lavage fluid; HE4: human epididymis protein 4.
HE4 as a new diagnostic biomarker for RA-ILD / T. Lin et al.

**Clinical value of HE4 in the diagnosis of ILD in RA patients**

The predictive power of serum and BALF HE4 for detecting the presence of ILD in RA patients was calculated by Receiver operating curve (ROC)/area under the curve (AUC) through plotting sensitivity against specificity. The predictive ROC/AUC of serum HE4 predictive power was 0.782 (95% CI: 0.683–0.881), with a sensitivity and specificity at 65.9% and 86%, respectively (the cut-off value was 111.1 pmol/l; Fig. 5); The predictive ROC/AUC of BALF HE4 predictive power was 0.856 (95% CI: 0.759–0.952), with a sensitivity and specificity at 63.1% and 90.0%, respectively (the cut-off value was 595 pmol/l; Fig. 5).

**Discussion**

To our knowledge, this is the first study to research the role of HE4 in RA patients. In this study, the HE4 levels of serum and BALF in RA-ILD patients were significantly higher than those in RA-no-ILD patients. Furthermore, the ROC curve further demonstrated that HE4 may be a potential biomarker in discriminating RA-ILD patients from RA patients. Moreover, the HE4 level was correlated with impairment in two parameters for ILD severity, including the decrease in DLCO pred% and higher fibrosis scores for ILD involvement identified in the HRCT. These results emphasise the potential for HE4 to be used as a novel diagnostic aid for RA-ILD.

HE4 is also known as the WFDC2 protein, which is a member of the whey acidic proteins family that displays a proteinase inhibitor function, and HE4 specifically inhibits the degradation of type I collagen by suppressing Prss35 and Prss23 serin protease activity (25, 26). The protein was originally identified as a transcript that is exclusively expressed in the epididymis and was proposed as being a specific marker for this tissue (25). HE4 has widely served as a routine clinical biomarker in the diagnosis and follow-up of patients with epithelial ovarian cancer (27). The United States Food and Drug Administration has approved HE4 as a biomarker to monitor the recurrence and the progression of ovarian cancer (28). HE4 has been found to be expressed in a number of normal human tissues outside of the male reproductive system, including the trachea, lung and nasal epithelium and was also found in a
subset of pulmonary epithelial-derived tumour cell lines (29). Within these tissues, HE4 is most readily detected in the excretory ducts of both the major and minor glands. The expression of HE4 at these sites suggests that it may be released into the secretions of the glands and the epithelium. HE4 has recently been identified as being a component of bronchoalveolar lavage (30). The exact function of HE4 has not been clearly illustrated; however, the protein has been suggested to function in the innate immune system in the lung (31, 32). It has antimicrobial and protease inhibitor activities and displays multiple biological activities in immunomodulation, anti-infection and fibrosis formation.

HE4 was identified as being a mediator in kidney fibrosis in human and mouse models, which indicated a functional role of HE4 in the formation of fibrosis (14). Significant increases in the expression and localisation of HE4 were observed in patients with cystic fibrosis. In addition, HE4 showed a positive correlation with the degree of lung impairment.

Our results, regarding the association between HE4 and ILD in RA patients, were similar to the findings by Zhang et al., who observed that the HE4 levels in serum and BALF were significantly elevated in patients with SSC who had ILD (20). In the present study, we also determined the diagnostic power of HE4 via ROC curve analyses. The AUC for serum HE4 was 0.782 (95% CI: 0.683–0.881) at the 111.1 pmol/L cut-off value, and the AUC for BALF HE4 was 0.856 (95% CI: 0.759–0.952) at the 595 pmol/L cut-off value for discriminating RA-ILD from RA, with appropriate qualities of sensitivity and specificity. Moreover, the multivariate logistic regression analysis demonstrated that the high levels of BALF HE4 (≥595 pmol/L) (odds ratio (OR)= 8.090; 95% CI=1.317–49.682; p=0.024) were significantly associated with RA-ILD.

Some studies have demonstrated that serum HE4 plays the role of a disease progression biomarker for some diseases, including ovarian cancer, chronic renal disease, pulmonary tuberculosis, cystic fibrosis and SSC-ILD (13, 15, 19, 33, 34). In our study, the serum and BALF HE4 concentrations showed a significant inverse correlation with DLCO% pred in RA-ILD patients. This result suggested that HE4 could be a potential biomarker for ILD and disease progression in RA patients. However, the specific mechanism of elevated HE4 levels in RA patients is unknown. We speculate that HE4 inhibited the activity of multiple matrix metalloproteinases, specifically inhibited their contribution to degrade collagen I and promoted fibrosis formation, which may be similar to the mechanics in SSC-ILD patients. However, further research is needed to confirm this hypothesis.

Until now, there has been no consensus on the definition of ILD in RA patients,

**Fig. 5.** Predictive capacity of serum HE4 and BALF HE4 in the presence of ILD in RA. HE4: human epididymis protein 4; BALF: bronchoalveolar lavage fluid; RA-ILD: rheumatoid arthritis-related interstitial lung disease.

**Table III.** Risk factors for ILD in patients with RA assessed by logistic regression analysis.

<table>
<thead>
<tr>
<th>variable</th>
<th>Odds ratio</th>
<th>95% confidence interval</th>
<th>p-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Univariate analysis</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Age (years)</td>
<td>1.075</td>
<td>1.021-1.131</td>
<td>0.006</td>
</tr>
<tr>
<td>Male</td>
<td>1.924</td>
<td>0.857-4.322</td>
<td>0.113</td>
</tr>
<tr>
<td>Smoking history</td>
<td>1.304</td>
<td>0.534-3.185</td>
<td>0.561</td>
</tr>
<tr>
<td>BMI (kg/m²)</td>
<td>1.069</td>
<td>0.857-1.334</td>
<td>0.552</td>
</tr>
<tr>
<td>RA disease duration (years)</td>
<td>1.011</td>
<td>0.967-1.056</td>
<td>0.628</td>
</tr>
<tr>
<td>DAS28 (units)</td>
<td>1.208</td>
<td>0.872-1.672</td>
<td>0.256</td>
</tr>
<tr>
<td>RF titre (IU/ml)</td>
<td>1.001</td>
<td>1.000-1.002</td>
<td>0.118</td>
</tr>
<tr>
<td>Anti-CCP antibody titre (IU/ml)</td>
<td>1.001</td>
<td>0.995-1.006</td>
<td>0.846</td>
</tr>
<tr>
<td>ESR (mm/h)</td>
<td>1.012</td>
<td>0.995-1.028</td>
<td>0.168</td>
</tr>
<tr>
<td>CRP (mg/dl)</td>
<td>1.006</td>
<td>0.996-1.017</td>
<td>0.244</td>
</tr>
<tr>
<td>Serum HE4&lt;sub&gt;≥111.1&lt;/sub&gt;</td>
<td>11.847</td>
<td>4.242-33.086</td>
<td>0.000</td>
</tr>
<tr>
<td>BALF HE4&lt;sub&gt;≥595&lt;/sub&gt;</td>
<td>16.923</td>
<td>5.327-131.152</td>
<td>0.000</td>
</tr>
<tr>
<td>Multivariate analysis</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Age (years)</td>
<td>1.054</td>
<td>0.975-1.139</td>
<td>0.186</td>
</tr>
<tr>
<td>Serum HE4&lt;sub&gt;≥111.1&lt;/sub&gt;</td>
<td>5.082</td>
<td>0.986-26.188</td>
<td>0.052</td>
</tr>
<tr>
<td>BALF HE4&lt;sub&gt;≥595&lt;/sub&gt;</td>
<td>8.090</td>
<td>1.317-49.682</td>
<td>0.024</td>
</tr>
</tbody>
</table>

HE4 as a new diagnostic biomarker for RA-ILD / T. Lin et al.

Clinical and Experimental Rheumatology 2022

found that HE4 had a positive correlation with HRCT fibrosis scores, which meant that a high HE4 level was an important discriminating factor of ILD, and that it may be a useful predictor for the severity of ILD in RA patients. One of any biomarkers alone may not be sufficient to completely and correctly screen/diagnose ILD in RA patients. Different biomarkers have various limitations. We speculated that a combination of biomarker assays may be more useful in clinical practice. Future studies based on a combination of biomarkers are needed to verify our preliminary findings.

Several studies investigating serum Krebs von den Lungen-6 (KL-6), surfactant protein D (SP-D) and second-generation anticicatrizating peptide antibodies (anti-CCP2) have been useful biomarkers for detecting ILD in RA patients. KL-6 is a mucin-like glycoprotein expressed on the surface membrane of alveolar and bronchiolar epithelial cells that has proinflammatory and anti-apoptotic effects on lung fibroblasts (38). Several studies investigating the clinical significance of KL-6 in RA patients have suggested that KL-6 serum levels are useful for detecting ILD and for evaluating disease activity. High levels of KL-6 were found to be correlated with low FVC and a high mortality rate (39). Surfactant protein D (SP-D), which is an alveolar epithelial marker, has been associated with preclinical and clinical RA-ILD (40). Anti-CCP2 antibodies could constitute an independent factor associated both with the presence and the severity of RA-ILD (41). Interestingly, in a recent study, the tumour markers CA125, CA19-9 and CEA were increased in RA-ILD and may play a role in occurrence and development, which may be diagnostic indicators for RA-ILD. Our study confirmed that serum and BALF HE4 levels were significantly increased in RA-ILD patients; a further analysis found that HE4 had a positive correlation with HRCT fibrosis scores, which meant that a high HE4 level was an important discriminating factor of ILD, and that it may be a useful predictor for the severity of ILD in RA patients. One of any biomarkers alone may not be sufficient to completely and correctly screen/diagnose ILD in RA patients. Different biomarkers have various limitations. We speculated that a combination of biomarker assays may be more useful in clinical practice. Future studies based on a combination of biomarkers are needed to verify our preliminary findings.

First, it was a single-centre cross-sectional study. Therefore, it was unable to demonstrate the causality of HE for the development of ILD in RA. Further studies using longitudinal data are required to establish exact and definite causal relationships. Second, the number of patients included in this study was relatively small. Third, this study lacked a validation cohort to confirm the results. In addition, the external validity of the results in other racial cohorts would also be an important aspect to validate. Finally, the lack of histopathological examination may also limit the value of the study. Direct serum/BALF-pathology correlations will be more convincing for determining HE4 as being a biomarker for RA-ILD.

Conclusions
In conclusion, this study aimed to identify new biomarkers in RA-ILD patients, which could facilitate the early diagnosis and treatment of this disease. The results showed that HE4 was markedly elevated in both the serum and BALF of RA-ILD patients. Moreover, there was a strong correlation of HE4 with ILD disease severity in RA patients. Therefore, HE4 could be a clinically useful biomarker in screening and evaluating RA-ILD patients.

Acknowledgements
We thank all the participants who agreed to enrol in the study and are grateful to the staff of the Lung Function Lab and Bronchoscope Lab at Yantai Yuhuangding Hospital for their assistance.

References
https://doi.org/10.1056/nejmra1004965
https://doi.org/10.1016/j.autrev.2021.102776
https://doi.org/10.1093/rheumatology/keq503
https://doi.org/10.1002/art.27405
https://doi.org/10.1093/rheumatology/keu165
https://doi.org/10.1164/jrccm.156.2.9609016
https://doi.org/10.1007/s13277-012-0356-9
https://doi.org/10.1515/cclm-2014-0041
https://doi.org/10.1016/j.cca.2016.06.010
HE4 as a new diagnostic biomarker for RA-ILD / T. Lin et al.


